{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:18:33Z","timestamp":1790504313995,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Leeds CRUK Centre"},{"DOI":"10.13039\/501100000777","name":"University of Leeds","doi-asserted-by":"publisher","award":["UAF"],"award-info":[{"award-number":["UAF"]}],"id":[{"id":"10.13039\/501100000777","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Triple negative breast cancers (TNBC) have poor prognoses despite aggressive treatment with cytotoxic chemotherapy. Cancer-associated fibroblasts (CAFs) are prominent in tumour stroma. Our hypothesis was that CAFs modulate chemotherapy sensitivity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>TNBC cells and breast fibroblasts were cultured; survival after chemotherapeutics was assessed using luciferase or clonogenic assays. Signalling was investigated using transcriptomics, reporters, recombinant proteins and blocking antibodies. Clinical relevance was investigated using immunohistochemistry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Breast CAFs dose-dependently protected TNBC cell lines MDA-MB-231 and MDA-MB-157, but not MDA-MB-468s, from chemotherapy. CAF-induced protection was associated with interferon (IFN) activation. CAFs were induced to express IFN\u03b21 by chemotherapy and TNBC co-culture, leading to paracrine activation in cancer cells. Recombinant IFNs were sufficient to protect MDA-MB-231 and MDA-MB-157 but not MDA-MB-468 cells. In TNBC patients, IFN\u03b21 expression in CAFs correlated with cancer cell expression of MX1, a marker of activated IFN signalling. High expression of IFN\u03b21 (CAFs) or MX1 (tumour cells) correlated with reduced survival after chemotherapy, especially in claudin-low tumours (which MDA-MB-231 and MDA-MB-157 cells represent). Antibodies that block IFN receptors reduced CAF-dependent chemoprotection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CAF-induced activation of IFN signalling in claudin-low TNBCs results in chemoresistance. Inhibition of this pathway represents a novel method to improve breast cancer outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-01226-4","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T18:03:51Z","timestamp":1609783431000},"page":"1110-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy"],"prefix":"10.1038","volume":"124","author":[{"given":"Robyn V.","family":"Broad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina C.","family":"Teske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Wastall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Hanby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3037-8528","authenticated-orcid":false,"given":"James L.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1169-3386","authenticated-orcid":false,"given":"Thomas A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"1226_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"1226_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.03.002","author":"A Ronchi","year":"2020","unstructured":"Ronchi, A., Pagliuca, F., Zito Marino, F., Accardo, M., Cozzolino, I. & Franco, R. Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma. Semin. Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2020.03.002 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"1226_CR3","doi-asserted-by":"publisher","first-page":"E734","DOI":"10.9778\/cmajo.20170030","volume":"5","author":"S Fallahpour","year":"2017","unstructured":"Fallahpour, S., Navaneelan, T., De, P. & Borgo, A. Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open 5, E734\u2013E739 (2017).","journal-title":"CMAJ Open"},{"key":"1226_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000507055","volume":"87","author":"L Annaratone","year":"2020","unstructured":"Annaratone, L., Cascardi, E., Vissio, E., Sarotto, I., Chmielik, E., Sapino, A. et al. The multifaceted nature of tumor microenvironment in breast carcinomas. Pathobiology 87, 125\u2013142 (2020).","journal-title":"Pathobiology"},{"key":"1226_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2015.02.018","volume":"361","author":"H Luo","year":"2015","unstructured":"Luo, H., Tu, G., Liu, Z. & Liu, M. Cancer-associated fibroblasts: a multifaceted driver of breast cancer progression. Cancer Lett. 361, 155\u2013163 (2015).","journal-title":"Cancer Lett."},{"key":"1226_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10555-018-9768-3","volume":"37","author":"JM Houthuijzen","year":"2018","unstructured":"Houthuijzen, J. M. & Jonkers, J. Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment. Cancer Metastasis Rev. 37, 577\u2013597 (2018).","journal-title":"Cancer Metastasis Rev."},{"key":"1226_CR7","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.7150\/jca.28054","volume":"9","author":"G Hu","year":"2018","unstructured":"Hu, G., Xu, F., Zhong, K., Wang, S., Huang, L. & Chen, W. Activated tumor-infiltrating fibroblasts predict worse prognosis in breast cancer patients. J. Cancer 9, 3736\u20133742 (2018).","journal-title":"J. Cancer"},{"key":"1226_CR8","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.7150\/jca.28583","volume":"9","author":"J Zhou","year":"2018","unstructured":"Zhou, J., Wang, X. H., Zhao, Y. X., Chen, C., Xu, X. Y., Sun, Q. et al. Cancer-associated fibroblasts correlate with tumor-associated macrophages infiltration and lymphatic metastasis in triple negative breast cancer patients. J. Cancer 9, 4635\u20134641 (2018).","journal-title":"J. Cancer"},{"key":"1226_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0960-z","volume":"18","author":"J Plava","year":"2019","unstructured":"Plava, J., Cihova, M., Burikova, M., Matuskova, M., Kucerova, L. & Miklikova, S. Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer. Mol. Cancer 18, 67 (2019).","journal-title":"Mol. Cancer"},{"key":"1226_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05220-6","volume":"9","author":"AS Cazet","year":"2018","unstructured":"Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C. L. et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat. Commun. 9, 2897 (2018).","journal-title":"Nat. Commun."},{"key":"1226_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3389\/fonc.2018.00337","volume":"8","author":"MH Joyce","year":"2018","unstructured":"Joyce, M. H., Lu, C., James, E. R., Hegab, R., Allen, S. C., Suggs, L. J. et al. Phenotypic basis for matrix stiffness-dependent chemoresistance of breast cancer cells to doxorubicin. Front. Oncol. 8, 337 (2018).","journal-title":"Front. Oncol."},{"key":"1226_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5449-z","volume":"19","author":"HY Smeland","year":"2019","unstructured":"Smeland, H. Y., Lu, N., Karlsen, T. V., Salvesen, G., Reed, R. K. & Stuhr, L. Stromal integrin alpha11-deficiency reduces interstitial fluid pressure and perturbs collagen structure in triple-negative breast xenograft tumors. BMC Cancer 19, 234 (2019).","journal-title":"BMC Cancer"},{"key":"1226_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.18632\/oncotarget.22922","volume":"9","author":"SL Ham","year":"2018","unstructured":"Ham, S. L., Thakuri, P. S., Plaster, M., Li, J., Luker, K. E., Luker, G. D. et al. Three-dimensional tumor model mimics stromal-breast cancer cells signaling. Oncotarget 9, 249\u2013267 (2018).","journal-title":"Oncotarget"},{"key":"1226_CR14","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.2353\/ajpath.2010.090838","volume":"176","author":"M Lorger","year":"2010","unstructured":"Lorger, M. & Felding-Habermann, B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am. J. Pathol. 176, 2958\u20132971 (2010).","journal-title":"Am. J. Pathol."},{"key":"1226_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2559.2011.03917.x","volume":"59","author":"ET Verghese","year":"2011","unstructured":"Verghese, E. T., Shenoy, H., Cookson, V. J., Green, C. A., Howarth, J., Partanen, R. H. et al. Epithelial-mesenchymal interactions in breast cancer: evidence for a role of nuclear localized beta-catenin in carcinoma-associated fibroblasts. Histopathology 59, 609\u2013618 (2011).","journal-title":"Histopathology"},{"key":"1226_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/path.4248","volume":"231","author":"ET Verghese","year":"2013","unstructured":"Verghese, E. T., Drury, R., Green, C. A., Holliday, D. L., Lu, X., Nash, C. et al. MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. J. Pathol. 231, 388\u2013399 (2013).","journal-title":"J. Pathol."},{"key":"1226_CR17","doi-asserted-by":"publisher","first-page":"e1000778","DOI":"10.1371\/journal.ppat.1000778","volume":"6","author":"J Mankouri","year":"2010","unstructured":"Mankouri, J., Fragkoudis, R., Richards, K. H., Wetherill, L. F., Harris, M., Kohl, A. et al. Optineurin negatively regulates the induction of IFNbeta in response to RNA virus infection. PLoS Pathog. 6, e1000778 (2010).","journal-title":"PLoS Pathog."},{"key":"1226_CR18","doi-asserted-by":"publisher","first-page":"W305","DOI":"10.1093\/nar\/gkp427","volume":"37","author":"J Chen","year":"2009","unstructured":"Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305\u2013W311 (2009).","journal-title":"Nucleic Acids Res."},{"key":"1226_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"1226_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/bjc.2016.178","volume":"115","author":"RA Millican-Slater","year":"2016","unstructured":"Millican-Slater, R. A., Sayers, C. D., Hanby, A. M. & Hughes, T. A. Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer. Br. J. Cancer 115, 339\u2013345 (2016).","journal-title":"Br. J. Cancer"},{"key":"1226_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1158\/1535-7163.MCT-19-0940","volume":"19","author":"WS Al Amri","year":"2020","unstructured":"Al Amri, W. S., Allinson, L. M., Baxter, D. E., Bell, S. M., Hanby, A. M., Jones, S. J. et al. Genomic and expression analyses define MUC17 and PCNX1 as predictors of chemotherapy response in breast cancer. Mol. Cancer Ther. 19, 945\u2013955 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"1226_CR22","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1136\/jcp.2006.044537","volume":"60","author":"I Zlobec","year":"2007","unstructured":"Zlobec, I., Steele, R., Terracciano, L., Jass, J. R. & Lugli, A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J. Clin. Pathol. 60, 1112\u20131116 (2007).","journal-title":"J. Clin. Pathol."},{"key":"1226_CR23","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","volume":"20","author":"FJ Barrat","year":"2019","unstructured":"Barrat, F. J., Crow, M. K. & Ivashkiv, L. B. Interferon target-gene expression and epigenomic signatures in health and disease. Nat. Immunol. 20, 1574\u20131583 (2019).","journal-title":"Nat. Immunol."},{"key":"1226_CR24","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1016\/j.febslet.2012.06.047","volume":"586","author":"J Zhang","year":"2012","unstructured":"Zhang, J., Zhao, H., Chen, J., Xia, B., Jin, Y., Wei, W. et al. Interferon-beta-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. FEBS Lett. 586, 3255\u20133262 (2012).","journal-title":"FEBS Lett."},{"key":"1226_CR25","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.4049\/jimmunol.1000491","volume":"185","author":"P Wang","year":"2010","unstructured":"Wang, P., Hou, J., Lin, L., Wang, C., Liu, X., Li, D. et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J. Immunol. 185, 6226\u20136233 (2010).","journal-title":"J. Immunol."},{"key":"1226_CR26","first-page":"1283","volume":"27","author":"S Ricardo","year":"2012","unstructured":"Ricardo, S., Gerhard, R., Cameselle-Teijeiro, J. F., Schmitt, F. & Paredes, J. Claudin expression in breast cancer: High or low, what to expect? Histol. Histopathol. 27, 1283\u20131295 (2012).","journal-title":"Histol. Histopathol."},{"key":"1226_CR27","doi-asserted-by":"crossref","unstructured":"Dias, K., Dvorkin-Gheva, A., Hallett, R. M., Wu, Y., Hassell, J., Pond, G. R. et al. Claudin-low breast cancer; clinical & pathological characteristics. PLoS ONE 12, e0168669 (2017).","DOI":"10.1371\/journal.pone.0168669"},{"key":"1226_CR28","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.108.827618","volume":"119","author":"RE Eid","year":"2009","unstructured":"Eid, R. E., Rao, D. A., Zhou, J., Lo, S. F., Ranjbaran, H., Gallo, A. et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119, 1424\u20131432 (2009).","journal-title":"Circulation"},{"key":"1226_CR29","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.4049\/jimmunol.180.8.5250","volume":"180","author":"HP Moll","year":"2008","unstructured":"Moll, H. P., Freudenthaler, H., Zommer, A., Buchberger, E. & Brostjan, C. Neutralizing type I IFN antibodies trigger an IFN-like response in endothelial cells. J. Immunol. 180, 5250\u20135256 (2008).","journal-title":"J. Immunol."},{"key":"1226_CR30","doi-asserted-by":"crossref","unstructured":"Vagia, E., Mahalingam, D. & Cristofanilli, M. The landscape of targeted therapies in TNBC. Cancers 12, 916 (2020).","DOI":"10.3390\/cancers12040916"},{"key":"1226_CR31","doi-asserted-by":"crossref","unstructured":"Nedeljkovic, M. & Damjanovic, A. Mechanisms of chemotherapy resistance in triple-negative breast cancer\u2014how we can rise to the challenge. Cells 8, 957 (2019).","DOI":"10.3390\/cells8090957"},{"key":"1226_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1117-0","volume":"15","author":"AN Hosein","year":"2015","unstructured":"Hosein, A. N., Livingstone, J., Buchanan, M., Reid, J. F., Hallett, M. & Basik, M. A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer. BMC Cancer 15, 130 (2015).","journal-title":"BMC Cancer"},{"key":"1226_CR33","doi-asserted-by":"publisher","first-page":"10728","DOI":"10.18632\/oncotarget.3828","volume":"6","author":"M Peiris-Pages","year":"2015","unstructured":"Peiris-Pages, M., Sotgia, F. & Lisanti, M. P. Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells. Oncotarget 6, 10728\u201310745 (2015).","journal-title":"Oncotarget"},{"key":"1226_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10549-020-05646-x","volume":"181","author":"AI Aljohani","year":"2020","unstructured":"Aljohani, A. I., Joseph, C., Kurozumi, S., Mohammed, O. J., Miligy, I. M., Green, A. R. et al. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Res. Treat. 181, 541\u2013551 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"1226_CR35","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/14728222.2020.1751819","volume":"24","author":"R Lappano","year":"2020","unstructured":"Lappano, R., Rigiracciolo, D. C., Belfiore, A., Maggiolini, M. & De Francesco, E. M. Cancer associated fibroblasts: role in breast cancer and potential as therapeutic targets. Expert Opin. Ther. Targets 24, 559\u2013572 (2020).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1226_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cell.2014.09.051","volume":"159","author":"MC Boelens","year":"2014","unstructured":"Boelens, M. C., Wu, T. J., Nabet, B. Y., Xu, B., Qiu, Y., Yoon, T. et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 159, 499\u2013513 (2014).","journal-title":"Cell"},{"key":"1226_CR37","doi-asserted-by":"crossref","unstructured":"Diana, A., Carlino, F., Franzese, E., Oikonomidou, O., Criscitiello, C., De Vita, F. et al. Early triple negative breast cancer: conventional treatment and emerging therapeutic landscapes. Cancers 12, 819 (2020).","DOI":"10.3390\/cancers12040819"},{"key":"1226_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2217\/imt-2020-0017","volume":"12","author":"E Anderson","year":"2020","unstructured":"Anderson, E. & Furie, R. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations. Immunotherapy 12, 275\u2013286 (2020).","journal-title":"Immunotherapy"},{"key":"1226_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10549-018-4770-6","volume":"170","author":"J O\u2019Shaughnessy","year":"2018","unstructured":"O\u2019Shaughnessy, J., DeMichele, A., Ma, C. X., Richards, P., Yardley, D. A., Wright, G. S. et al. A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. Breast Cancer Res. Treat. 170, 547\u2013557 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"1226_CR40","doi-asserted-by":"publisher","first-page":"R76","DOI":"10.1186\/gb-2007-8-5-r76","volume":"8","author":"JI Herschkowitz","year":"2007","unstructured":"Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z. et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8, R76\u2013R76 (2007).","journal-title":"Genome Biol."},{"key":"1226_CR41","first-page":"377","volume":"9","author":"AF Logullo","year":"2018","unstructured":"Logullo, A. F., Pasini, F. S., Nonogaki, S., Rocha, R. M., Soares, F. A. & Brentani, M. M. Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: a large diagnostic study using tissue microarray. Mol. Clin. Oncol. 9, 377\u2013388 (2018).","journal-title":"Mol. Clin. Oncol."},{"key":"1226_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0499-y","author":"Q Zhao","year":"2020","unstructured":"Zhao, Q., Bi, Y., Zhong, J., Li, X., Guo, J., Liu, Y.-X. et al. 10,11-dehydrocurvularin exerts antitumor effect against human breast cancer by suppressing STAT3 activation. Acta Pharmacol. Sin. https:\/\/doi.org\/10.1038\/s41401-020-0499-y (2020).","journal-title":"Acta Pharmacol. Sin."},{"key":"1226_CR43","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/15384047.2020.1750297","volume":"21","author":"O Odnokoz","year":"2020","unstructured":"Odnokoz, O., Yu, P., Peck, A. R., Sun, Y., Kovatich, A. J., Hooke, J. A. et al. Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biol. Ther. 21, 629\u2013636 (2020).","journal-title":"Cancer Biol. Ther."},{"key":"1226_CR44","doi-asserted-by":"publisher","first-page":"BSR20171672","DOI":"10.1042\/BSR20171672","volume":"38","author":"K Alsamman","year":"2018","unstructured":"Alsamman, K. & El-Masry, O. S. Interferon regulatory factor 1 inactivation in human cancer. Biosci. Rep. 38, BSR20171672 (2018).","journal-title":"Biosci. Rep."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01226-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T01:02:46Z","timestamp":1641258166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01226-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,16]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01226-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"29 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical permissions for use of patient material and data from patients was granted by Leeds (East) REC (references 09\/H1326\/108 and 06\/Q1206\/180). Patients recruited and informed consent was taken in line with these permissions. The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"\u0100ll data are available either within the manuscript and supplementary material, or directly from the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"R.V.B. was supported by Breast Cancer Action (charity #1170369-9) and a studentship from the University of Leeds. J.L.T. was supported by a University Academic Fellowship from the University of Leeds. L.M.W. was supported by a fellowship from the Leeds CRUK Cancer Centre.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}